CFSMN - Overview: Cystic Fibrosis and Spinal Muscular Atrophy Carrier Screen Panel, Varies
Reproductive risk refinement via carrier screening for individuals in the general population for cystic fibrosis and spinal muscular atrophy. Reproductive risk refinement via carrier screening for individuals with a family history of...
CHLAP - Overview: Chlamydia IgM and IgG Panel, Immunofluorescence, Serum
Aiding in the clinical diagnosis of Chlamydia pneumoniae or Chlamydia psittaci infection
TYRSC - Overview: Tyrosinemia Follow-Up Panel, Self-Collect, Blood Spot
Monitoring of individuals with tyrosinemia type I (hepatorenal tyrosinemia) using a patient-collected specimen
DRVI4 - Overview: Dilute Russell's Viper Venom Time (DRVVT) Interpretation
Interpreting mixing and confirmation assays for lupus anticoagulants
NCLBS - Overview: Neuronal Ceroid Lipofuscinosis, Two-Enzyme Panel, Blood Spot
Supporting the biochemical diagnosis of two neuronal ceroid lipofuscinoses, CLN1 and CLN2 This test is not useful for carrier detection.
FPNAP - Overview: Pneumococcal Antibody Panel (12 Serotype)
Pneumococcal Antibody Panel (12 Serotype)
PCDES - Overview: Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Evaluating children with autoimmune central nervous system disorders using serum specimens
BMAMA - Overview: Basic Metabolic Panel, Serum
Routine health monitoring or patient monitoring while hospitalized for information regarding metabolism, including the current kidney status, electrolyte, and acid/base balance, and blood glucose
Determining class II human leukocyte antigens (HLA) to identify potential disease associations or markers for drug hypersensitivity
SFGP - Overview: Spotted Fever Group Antibody, IgG and IgM, Serum
Aiding in the diagnosis of spotted fever group rickettsial infections
Mayo Clinic Ranked No. 1 Hospital Nationwide by U.S. News & World Report - Insights
Report’s 29th annual "Best Hospitals Honor Roll" published online on August 14. Mayo Clinic also ranked No. 1 in more specialties than any other hospital in the country....
NELL-1 [Test in Focus] - Insights
D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic...
Looking Back on Clinical Chemistry 1 - Insights
in the Mayo Clinic Medical Laboratory Science program, takes a look back on her Clinical Chemistry 1 course....
Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections....
Orexin-A/Hypocretin-1 for the Diagnosis of Type 1 Narcolepsy [Test in Focus] - Insights
test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy....